KNSA250516C35000
- 0.00
- 0.000.00%
Kiniksa Pharmaceuticals International Newsroom
Examining the Future: Kiniksa Pharmaceuticals's Earnings Outlook
Earnings Preview: KNSA to Report Financial Results Pre-market on April 29
Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $370,475, According to a Recent SEC Filing
Wedbush Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $34
Express News | Wedbush Reiterates Outperform on Kiniksa Pharmaceuticals, Maintains $34 Price Target
Evercore ISI Sticks to Their Buy Rating for Kiniksa Pharmaceuticals (KNSA)
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $30
Insider Sale: CHIEF FINANCIAL OFFICER of $KNSA Sells 8,879 Shares
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
New York Manufacturing Hits Low, Inflation Fears Rise
Citi Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $40
Kiniksa Pharmaceuticals Analyst Ratings
Express News | Kiniksa Pharmaceuticals Ltd : Citigroup Initiates Coverage With Buy Rating; Price Target $40
Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst
Kiniksa Pharmaceuticals International, Plc (NASDAQ:KNSA) Looks Inexpensive But Perhaps Not Attractive Enough
Is Kiniksa Pharmaceuticals International, Plc (KNSA) the Best Small Cap Pharma Stocks to Buy Now?
Evercore Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $35
Goldman Sachs Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $32